Unique microRNAs appear at different times during the course of a delayed-type hypersensitivity reaction in human skin

Diphencyprone (DPCP) is a hapten that induces delayed‐type hypersensitivity (DTH) reactions. MicroRNAs (miRNAs) are short non‐coding RNAs that negatively regulate gene expression and have been implicated in various inflammatory skin diseases, but their role in DTH reactions is not well understood. W...

Full description

Saved in:
Bibliographic Details
Published in:Experimental dermatology 2015-12, Vol.24 (12), p.953-957
Main Authors: Gulati, Nicholas, Løvendorf, Marianne B., Zibert, John R., Akat, Kemal M., Renwick, Neil, Tuschl, Thomas, Krueger, James G.
Format: Article
Language:English
Subjects:
Adult
Alopecia
Atopic dermatitis
Cell activation
Cyclopropanes - immunology
delayed-type hypersensitivity
diphencyprone
Female
Gene expression
Haptens - immunology
Humans
Hypersensitivity (delayed)
Hypersensitivity, Delayed - genetics
Hypersensitivity, Delayed - immunology
Hypersensitivity, Delayed - metabolism
Inflammation
Lymphocytes T
Male
Melanoma
microRNA
MicroRNAs
MicroRNAs - genetics
MicroRNAs - metabolism
Middle Aged
miRNA
next-generation sequencing
Psoriasis
Skin - immunology
Skin - metabolism
Skin diseases
Time Factors
Transcriptome
Young Adult
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Diphencyprone (DPCP) is a hapten that induces delayed‐type hypersensitivity (DTH) reactions. MicroRNAs (miRNAs) are short non‐coding RNAs that negatively regulate gene expression and have been implicated in various inflammatory skin diseases, but their role in DTH reactions is not well understood. We generated global miRNA expression profiles (using next‐generation sequencing) of DPCP reactions in skin of seven healthy volunteers at 3, 14 and 120 days after challenge. Compared to placebo‐treated sites, DPCP‐challenged skin at 3 days (peak inflammation) had 127 miRNAs significantly deregulated. At 14 days (during resolution of inflammation), 43 miRNAs were deregulated and, at 120 days (when inflammation had completely resolved), six miRNAs were upregulated. While some miRNAs have been observed in psoriasis or atopic dermatitis, most of the deregulated miRNAs have not yet been studied in the context of skin biology or immunology. Across the three time points studied, many but not all miRNAs were uniquely expressed. As various miRNAs may influence T cell activation, this may indicate that the miRNAs exclusively expressed at different time points function to promote or resolve skin inflammation, and therefore, may inform on the paradoxical ability of DPCP to treat both autoimmune conditions (alopecia areata) and conditions of ineffective immunity (melanoma).
ISSN:0906-6705
1600-0625
DOI:10.1111/exd.12813